Chang Irene J, He Miao, Lam Christina T
Division of Biochemical Genetics, Department of Pediatrics, University of Washington, Seattle, Washington, USA.
Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Ann Transl Med. 2018 Dec;6(24):477. doi: 10.21037/atm.2018.10.45.
Congenital disorders of glycosylation are a genetically and clinically heterogeneous group of >130 diseases caused by defects in various steps along glycan modification pathways. The vast majority of these monogenic diseases are autosomal recessive and have multi-systemic manifestations, mainly growth failure, developmental delay, facial dysmorphisms, and variable coagulation and endocrine abnormalities. Carbohydrate deficient transferrin (CDT) and protein-linked glycan analysis with mass spectrometry can diagnose some subtypes of congenital disorders of glycosylation (CDG), while many currently rely on massively parallel genomic sequencing for diagnosis. Early detection is important, as a few of these disorders are treatable. Molecular and biochemical techniques continue to further our understanding of this rapidly expanding group of clinically and genetically diverse disorders.
糖基化先天性疾病是一组遗传和临床异质性疾病,由聚糖修饰途径中各个步骤的缺陷引起,目前已知超过130种。这些单基因疾病绝大多数为常染色体隐性遗传,具有多系统表现,主要包括生长发育迟缓、面部畸形,以及凝血和内分泌异常。碳水化合物缺乏转铁蛋白(CDT)和蛋白质连接聚糖的质谱分析可诊断某些糖基化先天性疾病(CDG)亚型,而目前许多病例仍依赖大规模平行基因组测序进行诊断。早期检测很重要,因为其中一些疾病是可治疗的。分子和生化技术不断加深我们对这一迅速扩大的临床和遗传异质性疾病组的理解。